OVERVIEW

Key Insights: Lymphoma and Myeloma 2018 - A Focus on Chronic Lymphocytic Leukemia is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
This educational activity is designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
0.50 CME
0.50 CNE
0.50 CPE

Course Overview:
Clinicians who treat hematologic malignancies in 2018 have more insight into the inner molecular mechanisms of leukemias, lymphoma, and myeloma and have more treatment options than at any previous time in medical history. Today’s hematologists/oncologists, physician assistants, nurse practitioners, and other healthcare professionals who manage patients with hematologic malignancies must keep pace with a disconcertingly massive deluge of information on both nascent and established treatment options such as chemotherapies, targeted therapies, and immunotherapies in different sequences and combinations, as well as nonpharmacologic approaches. The intricacies of treatment are further compounded by patient variables such as whether the disease is newly diagnosed or relapsed/refractory and if the patient is generally fit and healthy or frail and fragile.

This activity intended to extend the reach of the content presented during L&M 2018 to clinicians who were unable to participate in the live congress, and to reinforce key points discussed in therapy area of lymphoma, myeloma and leukemia.

Course Objectives:
• Interpret efficacy and safety results from recent clinical trials of new pharmacologic agents for the treatment of leukemias, lymphomas, or myeloma
• Devise tailored therapeutic strategies designed to realize optimal therapeutic response from hematologic cancer patients
• Describe the mechanisms of action of new or emerging treatments that are designed to target molecular biomarkers or genetic aberrations that are frequently observed in hematologic cancers
• Assess both established and recently pioneered sequencing and combination strategies for second-line or salvage therapy interventions

Additional details will be posted as soon as they are available.